No Data
No Data
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright analyst Joseph Pantginis maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rat
Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Is It Too Late to Buy Iovance Biotherapeutics Stock?
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities